We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
-7.28%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.53B
AUM Growth
-$382M
Cap. Flow
+$195M
Cap. Flow %
2.99%
Top 10 Hldgs %
59.37%
Holding
305
New
83
Increased
54
Reduced
76
Closed
50

Sector Composition

Rank Sector Weight
1 Healthcare 34.38%
2 Consumer Staples 6.6%
3 Technology 4.23%
4 Consumer Discretionary 3.89%
5 Communication Services 1.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GMVDW
301
DELISTED
G Medical Innovations Holdings Ltd. Warrants
GMVDW
-28,571
Closed -$87.7K
SPPI
302
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
-20,000,000
Closed -$19.2M
MDGSW
303
DELISTED
Medigus Ltd. Series C Warrant
MDGSW
-85,714
Closed -$5.06K
HZNP
304
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
-88,000
Closed -$9.05M
ATVI
305
DELISTED
Activision Blizzard
ATVI
-108,000
Closed -$9.1M

Similar funds

Armistice Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Armistice Capital held 305 positions worth $6.53B, down 5.5% from $6.91B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Armistice Capital's Q3 2023 filing shows 83 new, 54 increased, 76 reduced and 50 closed positions. Its largest new stake was AB InBev: 703,000 shares worth $38.9M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $93.3M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, down from 39% a quarter earlier, followed by Consumer Staples and Technology.

  • Armistice Capital's largest Q3 2023 buy was AB InBev: 703,000 shares worth $38.9M.
  • Armistice Capital added most to PTC Therapeutics in Q3 2023, an estimated $108M increase.
  • Armistice Capital's biggest Q3 2023 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $93.3M.
  • Armistice Capital fully exited Pfizer in Q3 2023, selling an estimated $76.9M.
  • Armistice Capital's ten largest holdings make up 59% of its $6.53B portfolio in Q3 2023.
  • Armistice Capital opened 83 new positions and closed 50 in Q3 2023.
  • Armistice Capital's portfolio value fell 5.5% quarter-over-quarter to $6.53B.

Based on Armistice Capital's 13F filing for Q3 2023, filed 14 Nov 2023.